留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

多囊卵巢综合征患者血清miR-143-3p、miR-222-3p及抗苗勒管激素水平检测及其临床价值

林燕玲 王瑛 黄颀 康灵 邢维珍

林燕玲, 王瑛, 黄颀, 康灵, 邢维珍. 多囊卵巢综合征患者血清miR-143-3p、miR-222-3p及抗苗勒管激素水平检测及其临床价值[J]. 中华全科医学, 2022, 20(11): 1881-1883. doi: 10.16766/j.cnki.issn.1674-4152.002726
引用本文: 林燕玲, 王瑛, 黄颀, 康灵, 邢维珍. 多囊卵巢综合征患者血清miR-143-3p、miR-222-3p及抗苗勒管激素水平检测及其临床价值[J]. 中华全科医学, 2022, 20(11): 1881-1883. doi: 10.16766/j.cnki.issn.1674-4152.002726
LIN Yan-ling, WANG Ying, HUANG Qi, KANG Ling, XING Wei-zhen. Detection and clinical value of serum levels of miR-143-3p, miR-222-3p and AMH in patients with polycystic ovary syndrome[J]. Chinese Journal of General Practice, 2022, 20(11): 1881-1883. doi: 10.16766/j.cnki.issn.1674-4152.002726
Citation: LIN Yan-ling, WANG Ying, HUANG Qi, KANG Ling, XING Wei-zhen. Detection and clinical value of serum levels of miR-143-3p, miR-222-3p and AMH in patients with polycystic ovary syndrome[J]. Chinese Journal of General Practice, 2022, 20(11): 1881-1883. doi: 10.16766/j.cnki.issn.1674-4152.002726

多囊卵巢综合征患者血清miR-143-3p、miR-222-3p及抗苗勒管激素水平检测及其临床价值

doi: 10.16766/j.cnki.issn.1674-4152.002726
基金项目: 

海南省医药卫生科研基金项目 19A200193

海南省临床医学中心建设项目 琼卫(2021)75号

详细信息
    通讯作者:

    林燕玲, E-mail: lyl_841220@163.com

  • 中图分类号: R711.75 R446.11

Detection and clinical value of serum levels of miR-143-3p, miR-222-3p and AMH in patients with polycystic ovary syndrome

  • 摘要:   目的  探讨血清miR-143-3p、miR-222-3p水平联合抗苗勒管激素(AMH)在多囊卵巢综合征(PCOS)中的表达及临床价值。  方法  选取2018年1月—2022年3月三亚市妇女儿童医院收治的128例PCOS患者(PCOS组)和50例健康女性(对照组)。PCOS患者根据胰岛素抵抗指数(HOMA-IR)分为胰岛素抵抗组(83例,HOMA-IR≥2.69)和非胰岛素抵抗组(45例,HOMA-IR<2.69);根据BMI分为肥胖组(40例,BMI≥28)和非肥胖组(88例,BMI<28);根据睾酮水平分为高雄激素组(71例,睾酮≥0.7 ng/mL)及非高雄激素组(57例,睾酮<0.7 ng/mL)。采用实时定量PCR法检测血清miR-143-3p及miR-222-3p水平和电化学发光法检测AMH水平。ROC曲线分析miR-143-3p、miR-222-3p联合AMH对PCOS的诊断价值。相关性分析采用Pearson相关分析。  结果  PCOS组血清miR-143-3p、miR-222-3p及AMH水平均明显高于对照组,肥胖组明显高于非肥胖组,高雄激素组明显高于非高雄激素组,胰岛素抵抗组明显高于非胰岛素抵抗组,差异均有统计学意义(均P<0.001)。ROC曲线显示,miR-143-3p、miR-222-3p及AMH三项联合诊断PCOS的曲线下面积最大(AUC=0.910,95% CI:0.852~0.974)。PCOS患者血清miR-143-3p、miR-222-3p水平与AMH均呈正相关关系(r=0.842、0.795,均P<0.001)。  结论  PCOS患者血清miR-143-3p、miR-222-3p及AMH水平明显升高,三项联合检测对PCOS诊断具有较高的价值。

     

  • 图  1  miR-143-3p、miR-222-3p及AMH诊断PCOS的ROC曲线

    Figure  1.  ROC curve of diagnosing PCOS with miR-143-3p, miR-222-3p and AMH levels

    表  1  PCOS组和对照组临床资料比较(x±s)

    Table  1.   Comparison of clinical data between PCOS group and control group (x±s)

    组别 例数 年龄(岁) BMI 腰围(cm) 臀围(cm) 收缩压(mm Hg) 舒张压(mm Hg)
    对照组 50 28.95±4.12 23.37±2.45 72.40±8.27 86.35±5.34 116.83±12.26 71.42±7.68
    PCOS组 128 29.72±4.83 23.84±2.62 75.93±9.05 89.16±7.18 119.40±12.53 74.25±9.46
    t 0.962 1.105 1.594 1.353 0.672 0.735
    P 0.328 0.264 0.152 0.176 0.479 0.430
    组别 例数 空腹血糖(mmol/L) HOMA-IR LH(mIU/mL) FSH(mIU/mL) LH/FSH 睾酮(ng/mL)
    对照组 50 5.20±0.53 1.76±0.45 5.63±0.64 8.74±0.90 0.62±0.07 0.47±0.14
    PCOS组 128 5.74±1.65 4.60±2.57 8.40±0.75 6.91±0.38 1.26±0.15 1.77±0.38
    t 1.183 6.894 5.537 3.896 6.724 5.952
    P 0.241 <0.001 <0.001 0.012 <0.001 <0.001
    注:1 mm Hg=0.133 kPa。
    下载: 导出CSV

    表  2  PCOS组和对照组血清miR-143-3p、miR-222-3p及AMH水平比较(x±s)

    Table  2.   Comparison of serum miR-143-3p, miR-222-3p and AMH levels between PCOS group and control group (x±s)

    组别 例数 miR-143-3p miR-222-3p AMH(ng/mL)
    对照组 50 0.91±0.24 0.68±0.15 3.38±1.35
    PCOS组 128 2.96±1.17 1.73±0.66 9.86±2.74
    t 17.582 14.305 14.713
    P <0.001 <0.001 <0.001
    下载: 导出CSV

    表  3  肥胖组、非肥胖组和对照组血清miR-143-3p、miR-222-3p及AMH水平比较(x±s)

    Table  3.   Comparison of serum miR-143-3p, miR-222-3p and AMH levels between obese group and non obese group (x±s)

    组别 例数 miR-143-3p miR-222-3p AMH(ng/mL)
    对照组 50 0.91±0.24 0.68±0.15 3.38±1.35
    非肥胖组 88 1.16±0.35 0.75±0.20 4.20±1.46
    肥胖组 40 4.85±1.63ab 2.79±1.08ab 15.58±5.24ab
    F 21.152 16.625 19.583
    P <0.001 <0.001 <0.001
    注:与对照组比较,aP<0.001;与非肥胖组比较,bP<0.001。
    下载: 导出CSV

    表  4  高雄激素组、非高雄激素组和对照组血清miR-143-3p、miR-222-3p及AMH水平比较(x±s)

    Table  4.   Comparison of serum miR-143-3p, miR-222-3p and AMH levels between hyperandrogen group and non hyperandrogen group (x±s)

    组别 例数 miR-143-3p miR-222-3p AMH(ng/mL)
    对照组 50 0.91±0.24 0.68±0.15 3.38±1.35
    非高雄激素组 57 1.83±0.71a 1.42±0.46a 7.30±2.17a
    高雄激素组 71 4.06±1.45ab 2.02±0.84ab 12.69±4.18ab
    F 19.216 14.973 19.542
    P <0.001 <0.001 <0.001
    注:与对照组比较,aP<0.001;与非高雄激素组,bP<0.001。
    下载: 导出CSV

    表  5  胰岛素抵抗组、非胰岛素抵抗组和对照组血清miR-143-3p、miR-222-3p及AMH水平比较(x±s)

    Table  5.   Comparison of serum miR-143-3p, miR-222-3p and AMH levels between insulin resistance group and non insulin resistance group (x±s)

    组别 例数 miR-143-3p miR-222-3p AMH(ng/mL)
    对照组 50 0.91±0.24 0.68±0.15 3.38±1.35
    非胰岛素抵抗组 45 1.79±0.68a 1.38±0.43a 7.60±2.24a
    胰岛素抵抗组 83 4.13±1.47ab 2.10±0.86ab 12.42±4.13ab
    F 20.763 15.810 16.284
    P <0.001 <0.001 <0.001
    注:与对照组比较,aP<0.001;与非胰岛素抵抗组,bP<0.001。
    下载: 导出CSV

    表  6  血清miR-143-3p、miR-222-3p及AMH水平对PCOS的诊断价值

    Table  6.   Diagnostic value of serum levels of miR-143-3p, miR-222-3p and AMH in PCOS

    项目 最佳截断值 AUC 95% CI 灵敏度(%) 特异度(%) 阳性预测值(%) 阴性预测值(%)
    miR-143-3p 2.04 0.834 0.776~0.895 85.8 80.2 83.5 82.4
    miR-222-3p 1.28 0.787 0.731~0.850 81.6 74.8 72.0 79.5
    AMH(ng/mL) 6.97 0.814 0.755~0.871 83.5 76.0 79.2 80.8
    三项联合 0.910 0.852~0.974 96.0 78.7 83.0 92.4
    下载: 导出CSV
  • [1] STENER-VICTORIN E, DENG Q L. Epigenetic inheritance of polycystic ovary syndrome-challenges and opportunities for treatment[J]. Nat Rev Endocrinol, 2021, 17(9): 521-533. doi: 10.1038/s41574-021-00517-x
    [2] SADEGHI H M, ADELI I, CALINA D, et al. Polycystic ovary syndrome: A comprehensive review of pathogenesis, management, and drug repurposing[J]. Int J Mol Sci, 2022, 23(2): 583. doi: 10.3390/ijms23020583
    [3] 王昱欢, 丁奕岑, 蔡瑶雨, 等. 差异表达微RNA作为多囊卵巢综合征生物标志物的研究[J]. 上海交通大学学报(医学版), 2021, 41(11): 1429-1435. doi: 10.3969/j.issn.1674-8115.2021.11.005

    WANG Y H, DING Y C, CAI Y Y, et al. Study on differentially expressed microRNA as a biomarker of polycystic ovary syndrome[J]. Journal of Shanghai Jiaotong University (Medical Edition), 2021, 41(11): 1429-1435. doi: 10.3969/j.issn.1674-8115.2021.11.005
    [4] CAO J P, HUO P, CUI K Q, et al. Follicular fluid-derived exosomal miR-143-3p/miR-155-5p regulate follicular dysplasia by modulating glycolysis in granulosa cells in polycystic ovary syndrome[J]. Cell Commun Signal, 2022, 20(1): 61. doi: 10.1186/s12964-022-00876-6
    [5] YE H, LIU X J, HUI Y, et al. Downregulation of microRNA-222 reduces insulin resistance in rats with PCOS by inhibiting activation of the MAPK/ERK pathway via pten[J]. Mol Ther Nucleic Acids, 2020, 22(7): 733-741.
    [6] 秦薇, 黄筱竑, 黄慧莲. HIF-1α、VEGF及AMH在多囊卵巢综合征中的表达及其临床意义[J]. 中华全科医学, 2021, 19(10): 1693-1696. doi: 10.16766/j.cnki.issn.1674-4152.002144

    QIN W, HUANG X H, HUANG H L. Expression and clinical significance of HIF-1α, VEGF and AMH in patients with polycystic ovary syndrome[J]. Chinese Journal of General Practice, 2021, 19(10): 1693-1696. doi: 10.16766/j.cnki.issn.1674-4152.002144
    [7] 中华医学会妇产科学分会内分泌学组及指南专家组. 多囊卵巢综合征中国诊疗指南[J]. 中华妇产科杂志, 2018, 53(1): 2-6. https://www.cnki.com.cn/Article/CJFDTOTAL-SFCZ201810010.htm

    Endocrinology group and guideline expert group of Obstetrics and Gynecology branch of Chinese Medical Association. Chinese guidelines for diagnosis and treatment of polycystic ovary syndrome[J]. Chinese Journal of Obstetrics and Gynecology, 2018, 53(1): 2-6. https://www.cnki.com.cn/Article/CJFDTOTAL-SFCZ201810010.htm
    [8] FAROOQUI N, MAHA Q U. Role of some MiRNA affecting polycystic ovarian syndrome and SIRT1 levels[J]. J Pak Med Assoc, 2020, 70(5): 945.
    [9] WANG W, JI J, LI J, et al. Several critical genes and microRNAs associated with the development of polycystic ovary syndrome[J]. Ann Endocrinol (Paris), 2020, 81(1): 18-27. doi: 10.1016/j.ando.2019.10.002
    [10] 杨东霞, 申儒霞, 李红梅, 等. 微小RNA在多囊卵巢综合征发病机制中的研究进展[J]. 中国生育健康杂志, 2022, 33(1): 81-83, 89. https://www.cnki.com.cn/Article/CJFDTOTAL-SYJK202201021.htm

    YANG D X, SHEN R X, LI H M, et al. Research progress of microRNA in the pathogenesis of polycystic ovary syndrome[J]. Chinese Journal of Reproductive Health, 2022, 33(1): 81-83, 89. https://www.cnki.com.cn/Article/CJFDTOTAL-SYJK202201021.htm
    [11] BUTLER A E, RAMACHANDRAN V, HAYAT S, et al. Expression of microRNA in follicular fluid in women with and without PCOS[J]. Sci Rep, 2019, 9(1): 16306. DOI: 10.1038/s41598-019-52856-5.
    [12] DU J, RUAN X Y, JIN F Y, et al. Abnormalities of early folliculogenesis and serum anti-müllerian hormone in chinese patients with polycystic ovary syndrome[J]. J Ovarian Res, 2021, 14(1): 36. doi: 10.1186/s13048-021-00786-0
    [13] ZHAO Y Y, PAN S H, LI Y Y, et al. Exosomal miR-143-3p derived from follicular fluid promotes granulosa cell apoptosis by targeting BMPR1A in polycystic ovary syndrome[J]. Sci Rep, 2022, 12(1): 4359. DOI: 10.1038/s41598-022-08423-6.
    [14] HUANG X L, SHE L P, LUO X M, et al. MiR-222 promotes the progression of polycystic ovary syndrome by targeting p27 Kip1[J]. Pathol Res Pract, 2019, 215(5): 918-923. doi: 10.1016/j.prp.2019.01.038
    [15] LI X J, WANG H, LU D Y, et al. Anti-müllerian hormone accelerates pathological process of insulin resistance in polycystic ovary syndrome patients[J]. Horm Metab Res, 2021, 53(8): 504-511. doi: 10.1055/a-1499-7718
    [16] CHEN Z, OU H X, WU H L, et al. Role of microRNA in the pathogenesis of polycystic ovary syndrome[J]. DNA Cell Biol, 2019, 38(8): 754-762. doi: 10.1089/dna.2019.4622
    [17] SHI X Y, PENG D, LIU Y F, et al. Advantages of serum anti-müllerian hormone as a marker for polycystic ovarian syndrome[J]. Lab Med, 2019, 50(3): 236-242. doi: 10.1093/labmed/lmy068
  • 加载中
图(1) / 表(6)
计量
  • 文章访问数:  220
  • HTML全文浏览量:  38
  • PDF下载量:  1
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-05-02
  • 网络出版日期:  2022-12-30

目录

    /

    返回文章
    返回